JP2022174207A5 - - Google Patents

Download PDF

Info

Publication number
JP2022174207A5
JP2022174207A5 JP2022143550A JP2022143550A JP2022174207A5 JP 2022174207 A5 JP2022174207 A5 JP 2022174207A5 JP 2022143550 A JP2022143550 A JP 2022143550A JP 2022143550 A JP2022143550 A JP 2022143550A JP 2022174207 A5 JP2022174207 A5 JP 2022174207A5
Authority
JP
Japan
Prior art keywords
gene
stat1
ch25h
disease
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022143550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022174207A (ja
Filing date
Publication date
Priority claimed from JP2019563786A external-priority patent/JP7675502B2/ja
Application filed filed Critical
Publication of JP2022174207A publication Critical patent/JP2022174207A/ja
Publication of JP2022174207A5 publication Critical patent/JP2022174207A5/ja
Pending legal-status Critical Current

Links

JP2022143550A 2017-05-16 2022-09-09 アルツハイマー病の治療用組成物および治療方法 Pending JP2022174207A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762506782P 2017-05-16 2017-05-16
US62/506,782 2017-05-16
JP2019563786A JP7675502B2 (ja) 2017-05-16 2018-05-09 アルツハイマー病の治療用組成物および治療方法
PCT/US2018/031901 WO2018213081A1 (en) 2017-05-16 2018-05-09 Compositions and methods for treating alzheimer's disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019563786A Division JP7675502B2 (ja) 2017-05-16 2018-05-09 アルツハイマー病の治療用組成物および治療方法

Publications (2)

Publication Number Publication Date
JP2022174207A JP2022174207A (ja) 2022-11-22
JP2022174207A5 true JP2022174207A5 (https=) 2023-03-27

Family

ID=64274628

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019563786A Active JP7675502B2 (ja) 2017-05-16 2018-05-09 アルツハイマー病の治療用組成物および治療方法
JP2022143550A Pending JP2022174207A (ja) 2017-05-16 2022-09-09 アルツハイマー病の治療用組成物および治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019563786A Active JP7675502B2 (ja) 2017-05-16 2018-05-09 アルツハイマー病の治療用組成物および治療方法

Country Status (9)

Country Link
US (1) US11873321B2 (https=)
EP (1) EP3628008A4 (https=)
JP (2) JP7675502B2 (https=)
KR (1) KR20200010311A (https=)
CN (2) CN111132694B (https=)
AU (1) AU2018270906B2 (https=)
CA (1) CA3063217A1 (https=)
TW (1) TW201900216A (https=)
WO (1) WO2018213081A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200010311A (ko) * 2017-05-16 2020-01-30 제네로스 바이오파마 리미티드 알츠하이머병의 치료를 위한 조성물 및 방법
CN111500694B (zh) * 2019-01-31 2023-02-24 中国科学院脑科学与智能技术卓越创新中心 Baz2b基因作为靶点在缓解衰老中的应用
JP2023521646A (ja) * 2020-03-31 2023-05-25 ウィルフレッド ジェフリーズ アルツハイマー病の治療方法
CA3259413A1 (en) * 2022-06-13 2023-12-21 The University Of Queensland USES OF JAK INHIBITORS IN THE MANAGEMENT OF DEPRESSION AND CENTRAL NERVOUS SYSTEM (CNS) DISEASES ASSOCIATED WITH INFLAMMATION

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285526B2 (en) * 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
US20020188012A1 (en) * 1998-01-28 2002-12-12 Bisgaier Charles Larry Method for treating Alzheimer's disease
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US8771700B2 (en) * 2006-08-23 2014-07-08 Rutgers, The State University Of New Jersey Interferon antagonists, antibodies thereto and associated methods of use
US9272029B2 (en) * 2009-03-26 2016-03-01 Ibc Pharmaceuticals, Inc. Interferon lambada-antibody complexes
US9987224B2 (en) * 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
EP3140403A4 (en) * 2014-05-09 2017-12-20 Université Laval Prevention and treatment of alzheimer's disease by genome editing using the crispr/cas system
ES2731437T3 (es) * 2014-11-21 2019-11-15 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
KR20200010311A (ko) * 2017-05-16 2020-01-30 제네로스 바이오파마 리미티드 알츠하이머병의 치료를 위한 조성물 및 방법

Similar Documents

Publication Publication Date Title
JP2022174207A5 (https=)
JP2022191257A5 (https=)
JP2022095882A5 (ja) 医薬組成物
JP2024088668A5 (https=)
JP2005526107A5 (https=)
JP2021534129A5 (https=)
CA2530006A1 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
JP2023076465A5 (https=)
JP2006506425A5 (https=)
DE60107820D1 (de) Neue verwendung von phenylheteroalkylamin-derivaten
JP2005509662A5 (https=)
JP2013528655A5 (https=)
TNSN05163A1 (fr) Derives de pyrrolo-pyrazole substitues servant d'inhibiteurs de kinases
CN115315423A (zh) 取代芳基类化合物
JP2021528488A5 (https=)
Aufdemorte et al. Griseofulvin in the treatment of three cases of oral erosive lichen planus
JPH05163139A (ja) 抗動脈硬化剤
MA46268B1 (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
CA2526989A1 (en) Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
JP2017132781A5 (https=)
JP2021512921A5 (https=)
JP2023022236A5 (https=)
JP2006510606A5 (https=)
JP2004502684A5 (https=)
JP2010500284A5 (https=)